COPENHAGEN, Denmark & NEW YORK, USA, July 15, 2026
HERVolution Therapeutics ApS, a biotechnology company developing human endogenous retrovirus (HERV)-targeting immunotherapies, has presented new scientific evidence linking HERV-K activation to metabolic senescence, chronic inflammation, and obesity at the International Congress on Obesity (ICO 2026) in Mexico City. The findings provide compelling preclinical and clinical evidence demonstrating that HERV-K plays a central role in driving senescence-associated inflammation in metabolically stressed cells while also being reactivated in the plasma of individuals living with obesity. The research significantly expands the therapeutic potential of HERVolution’s innovative platform beyond oncology into metabolic diseases, insulin resistance, and healthy aging, highlighting a promising new biological pathway for the development of next-generation immunotherapies targeting chronic inflammatory disorders.
New Research Identifies HERV-K as a Key Driver of Metabolic Senescence
The oral presentation at ICO 2026, titled “Human Endogenous Retrovirus K Drives and Spreads Metabolic Senescence,” introduced mechanistic evidence demonstrating that HERV-K becomes activated under conditions of metabolic stress in terminally damaged cells. Researchers found that HERV-K is required for the initiation and amplification of adipocyte stress-associated inflammation, establishing a direct biological link between cellular senescence, chronic low-grade inflammation, and metabolically unhealthy obesity. The findings suggest that HERV-K is not merely associated with disease progression but functions as an active driver of inflammatory signaling pathways that contribute to metabolic dysfunction. By identifying this previously underappreciated mechanism, the study opens new opportunities for therapeutic intervention aimed at slowing disease progression while addressing one of the fundamental biological causes of obesity-related inflammation and tissue aging.
Clinical Data Strengthen HERV-K as a Therapeutic Target
Complementing the laboratory findings, HERVolution Therapeutics presented clinical evidence generated through collaborations with researchers at the University of Copenhagen and Bispebjerg-Frederiksberg Hospital, where elevated HERV-K reactivation was detected in plasma samples collected from volunteers living with obesity. The presence of circulating HERV-K activity provides the first human plasma-level evidence supporting its role in metabolic disease and validates earlier experimental observations. These clinical findings reinforce the possibility of using HERV-K not only as a therapeutic target but also as a potential biomarker for monitoring metabolic inflammation, cellular aging, and disease progression. Together, the combined preclinical and human clinical data substantially strengthen confidence in HERVolution’s HERV-targeting strategy and broaden its scientific relevance across multiple chronic diseases characterized by persistent inflammatory responses.
Advertisement
Expanding Immunotherapy Beyond Oncology into Metabolic Disease
HERVolution Therapeutics is pioneering a new class of HERV-targeting immunotherapies designed to harness the immune system against ancient viral elements embedded within the human genome that become reactivated during cancer and age-related diseases. While the company’s lead investigational candidate, IPT-001, is advancing toward first-in-human clinical studies for oncology, the latest findings demonstrate that the same platform may have significant applications in treating obesity, cardiometabolic disorders, insulin resistance, and diseases associated with accelerated aging. By targeting the biological mechanisms underlying cellular senescence rather than only treating disease symptoms, HERVolution aims to develop innovative therapies capable of addressing multiple chronic conditions through a single scientific platform. The research presented at ICO 2026 positions HERV-K as a promising therapeutic target for next-generation metabolic medicine and highlights the growing potential of precision immunotherapy to transform the treatment of obesity and inflammatory diseases.
Source: HERVolution Therapeutics press release
